Search Results - "FRISHMAN, W"

Refine Results
  1. 1

    Carvedilol by Frishman, William H

    Published in The New England journal of medicine (10-12-1998)
    “…Carvedilol is a β-adrenoreceptor–antagonist drug with α 1 -adrenoreceptor–antagonist activity. It was approved in the United States in September 1995 for the…”
    Get full text
    Journal Article
  2. 2

    Thyroid hormone and cardiovascular disease by Gomberg-Maitland, Mardi, Frishman, William H.

    Published in The American heart journal (01-02-1998)
    “…Thyroid hormone directly affects the heart and peripheral vascular system. The hormone can increase myocardial inotropy and heart rate and dilate peripheral…”
    Get full text
    Journal Article
  3. 3

    Serotonin and the heart by Frishman, W H, Grewall, P

    Published in Annals of medicine (Helsinki) (2000)
    “…Serotonin is a naturally occurring vasoactive substance that has diverse cardiophysiological effects. These effects can be explained by the existence of…”
    Get more information
    Journal Article
  4. 4

    Comparison of Self-Report, Hospital Discharge Codes, and Adjudication of Cardiovascular Events in the Women’s Health Initiative by Heckbert, Susan R., Kooperberg, Charles, Safford, Monika M., Psaty, Bruce M., Hsia, Judith, McTiernan, Anne, Gaziano, J. Michael, Frishman, William H., Curb, J. David

    Published in American journal of epidemiology (15-12-2004)
    “…Limited information is available from large clinical investigations about the agreement among sources of diagnoses for endpoints. The authors used data from…”
    Get full text
    Journal Article
  5. 5

    Sodium Ion/Hydrogen Ion Exchange Inhibition: A New Pharmacologic Approach to Myocardial Ischemia and Reperfusion Injury by Levitsky, Josh, Gurell, Daniel, Frishman, William H.

    Published in Journal of clinical pharmacology (01-10-1998)
    “…Over the past few years, it has been shown that the cardiac myocyte plasma membrane sodium ion/hydrogen ion exchanger (NHE) plays an important role in the…”
    Get full text
    Journal Article
  6. 6

    Student research projects and theses: should they be a requirement for medical school graduation? by Frishman, W H

    Published in Heart disease (Hagerstown, Md.) (01-05-2001)
    “…From 1981 to 1994, 69 fourth-year students at the Albert Einstein College of Medicine participated in a 6-month medical school research project (MSRP) with the…”
    Get more information
    Journal Article
  7. 7
  8. 8

    Women, myocardial infarction, and dementia in the very old by ARONSON, M. K, OOI, W. L, MORGENSTERN, H, HAFNER, A, MASUR, D, CRYSTAL, H, FRISHMAN, W. H, FISHER, D, KATZMAN, R

    Published in Neurology (01-07-1990)
    “…Dementia is a major public health problem among the very old. Available information on incidence and prevalence is sparse and variable; however, there appears…”
    Get full text
    Journal Article
  9. 9

    Development of dementing illnesses in an 80-year-old volunteer cohort by Katzman, R, Aronson, M, Fuld, P, Kawas, C, Brown, T, Morgenstern, H, Frishman, W, Gidez, L, Eder, H, Ooi, W L

    Published in Annals of neurology (01-04-1989)
    “…We have prospectively followed over a 5-year period 434 volunteers who were at intake ambulatory, functional, presumably nondemented, and between 75 and 85…”
    Get more information
    Journal Article
  10. 10

    Novel antiplatelet therapies for treatment of patients with ischemic heart disease : inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor by FRISHMAN, W. H, BURNS, B, ATAC, B, ALTURK, N, ALTAJAR, B, LERRICK, K

    Published in The American heart journal (01-10-1995)
    “…Blood platelets play essential roles in normal coagulation and in coronary atherosclerotic disease and its complications. Various antiplatelet therapies,…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Co-enzyme Q10: a new drug for cardiovascular disease by Greenberg, S, Frishman, W H

    Published in Journal of clinical pharmacology (01-07-1990)
    “…Co-enzyme Q10 (ubiquinone) is a naturally occurring substance which has properties potentially beneficial for preventing cellular damage during myocardial…”
    Get more information
    Journal Article
  13. 13

    β-adrenergic blockers in systemic hypertension. Pharmacokinetic considerations related to the current guidelines by FRISHMAN, William H, ALWARSHETTY, Mamata

    Published in Clinical pharmacokinetics (2002)
    “…Beta-adrenergic blockade has provided one of the major pharmacotherapeutic advances of the 20th century. Beta-blockers are first-line drugs for the management…”
    Get full text
    Journal Article
  14. 14

    Matrix Metalloproteinases and Coronary Artery Disease: A Novel Therapeutic Target by Celentano, Diane C., Frishman, William H.

    Published in Journal of clinical pharmacology (01-11-1997)
    “…Matrix metalloproteinases (MMP) are a family of enzymes that selectively digest individual components of the extracellular matrix. Their function has been…”
    Get full text
    Journal Article
  15. 15

    Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease by Frishman, W H, Huberfeld, S, Okin, S, Wang, Y H, Kumar, A, Shareef, B

    Published in Journal of clinical pharmacology (01-06-1995)
    “…Serotonin, or 5-hydroxytryptamine, is a naturally-occurring vasoactive substance found primarily in the brain, enterochromaffin tissue, and blood platelets. It…”
    Get more information
    Journal Article
  16. 16

    Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures by Landzberg, Brian R., Frishman, William H., Lerrick, Kenneth

    “…Percutaneous transluminal coronary angioplasty (PTCA) has become a mainstay in the treatment of ischemic heart disease, with an estimated 300,000 procedures…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Secondary prevention of myocardial infarction: Role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors by Frishman, William H., Cheng, Angela

    Published in The American heart journal (01-04-1999)
    “…β-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE)…”
    Get full text
    Journal Article
  19. 19

    Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system by Kang, P M, Landau, A J, Eberhardt, R T, Frishman, W H

    Published in The American heart journal (01-05-1994)
    “…A-II exerts its activity on various target tissues by binding to its receptors. The discovery of local RASs and A-II receptors within various tissues has…”
    Get more information
    Journal Article
  20. 20

    Matrix Metalloproteinases and Abdominal Aortic Aneurysms: A Potential Therapeutic Target by Sinha, Sanjai, Frishman, William H.

    Published in Journal of clinical pharmacology (01-12-1998)
    “…Abdominal aortic aneurysm (AAA) is a leading cause of death in the United States, and there is no effective treatment in the early course of disease. Therapy…”
    Get full text
    Journal Article